Bionomics Limited (ASX: BNO, OTCQX:BNOEF) to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP

Company Name: Bionomics

Announcement Date: 19/09/2016
Announcement Category: Awards/recognition, Other, Product launch/update
Announcement Content:

Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP

Bionomics Limited (ASX: BNO, OTCQX:BNOEF), a clinical stage biopharmaceutical company
focused on the discovery and development of innovative therapeutics for the treatment of diseases of
the central nervous system (CNS) and cancer, will present two posters at the European College of
Neuropsychopharmacology (ECNP) Congress in Vienna on Tuesday 20th September 2016.
One poster reports the results of the Phase 1b clinical trial completed in September 2015 in which
BNC210 demonstrated target engagement. The other poster showcases an animal model of
cognitive dysfunction which demonstrates the cognitive-enhancing efficacy of marketed drugs for
attention deficit hyperactivity disorder (ADHD).
The first poster, A multiple ascending dose study with evidence for target engagement of BNC210; a
negative allosteric modulator of alpha7 nAChR in development for anxiety, describes demonstration
of target engagement by BNC210 as measured by quantitative electroencephalogram (qEEG).
BNC210 is a negative allosteric modulator of the of the alpha 7 nicotinic acetylcholine receptor
(alpha7 nAChR) in development for the treatment of anxiety and stress-related disorders. Bionomics’
research has demonstrated that single ascending doses of BNC210 are safe, well tolerated and
avoid the side effects seen with standard of care drugs for anxiety such as benzodiazepines,
Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Norepinephrine Reuptake Inhibitors
(SNRIs).
This clinical trial investigated multiple ascending doses of BNC210 in healthy volunteers. Repeated
administrations of BNC210 produced no detrimental effects on cognitive functions and was safe and
well tolerated. A qEEG paradigm showed that BNC210 engaged with its target by inhibiting the
effects of nicotine on the brain
BNC210 possesses significant potential in meeting a medical need for fast-acting anxiolytic agents
that do not carry the side-effects of existing treatments such as sedation, addiction and negative
effects on memory and coordination.
The second poster, co-authored with Bionomics’ subsidiary, Neurofit SAS, presents data from an
animal model of cognitive dysfunction that demonstrates the cognitive-enhancing efficacy of
marketed drugs for ADHD; Strattera (Atomoxetine), Ritalin (methylphenidate) and Dexadrine (Damphetamine).
The model presents a novel method for assessing drugs in development for ADHD.
Copies of both posters will be available on Bionomics’ website: www.bionomics.com.au following
presentation at ECNP.
Bionomics is currently evaluating BNC210 in Phase II trials for generalized anxiety disorder for which
results are expected in Q3 2016, and post-traumatic stress disorder, which was initiated at the end of
Q2 2016.
ECNP is an independent scientific association dedicated to the science and treatment of disorders of
the brain. It is the largest non-institutional supporter of applied and translational neuroscience
research and education in Europe.
FOR FURTHER INFORMATION PLEASE CONTACT:
Australia US
Monsoon Communications Stern IR, Inc.
Rudi Michelson Beth Del Giacco
+613 9620 3333 +1 212 362 1200
[email protected] [email protected]
About Bionomics Limited
Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform
technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of
serious central nervous system disorders and on the treatment of cancer. Bionomics’ lead drug candidate BNC210,
currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel,
proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. The Company is also
developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is
overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101
entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD
outside the United States and Canada) in pain and cognition.
www.bionomics.com.au
Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States’ Private Securities
Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or
developments, including, without limitation, statements made regarding Bionomics’ drug candidates (including BNC210 and
BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery
programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to
be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and
similar expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause actual results or events to differ materially from those indicated by
these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical
trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or
platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our
intellectual property, risks related to our international operations, our inability to integrate acquired businesses and
technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies
performed on our drug candidates and competitors’ drugs and drug candidates may vary from those reported when tested
in different settings.
Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities
are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments
occurring after the date of this announcement

Bionomics is an Adelaide-based biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and Alzheimer's Disease. We are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. At the core of our business is strategic partnering. We partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible.

Go to Company Profile for: Bionomics

Announcement Contact: [email protected]